Table 3.
Resource Use of Tisagenlecleucel and Salvage Chemotherapy in EFS and PD/RL States
| Frequency of Visits/Tests in the EFS State | PD/RL | |||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Years 3–5 | Years 5+ | |||
| Consultant visit | Tisagenlecleucel | 12 | 4 | 2 | 2 | 6 |
| Salvage chemotherapy | 6 | 1 | ||||
| Blood tests | Tisagenlecleucel | 16 | 4 | 2 | 0 | 6 |
| Salvage chemotherapy | 6 | |||||
| Cerebrospinal fluid | Tisagenlecleucel | 1 | 0 | 0 | 0 | 1 |
| Salvage chemotherapy | 1 | |||||
| Electrocardiogram | Tisagenlecleucel | 1 | 0 | 0 | 0 | 0 |
| Salvage chemotherapy | 0 | |||||
| Bone marrow aspirate | Tisagenlecleucel | 3 | 0 | 0 | 0 | 1 |
| Salvage chemotherapy | 1 | |||||
| Bone marrow biopsy | Tisagenlecleucel | 3 | 0 | 0 | 0 | 0 |
| Salvage chemotherapy | 0 | |||||
| Echocardiogram | Tisagenlecleucel | 0 | 0 | 0 | 0 | 1 |
| Salvage chemotherapy | 1 | |||||
Notes: Resource use validated by clinical experts.
Abbreviations: EFS, event-free survival; PD/RL, progressive/relapsed disease.